Cargando…

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?

Detalles Bibliográficos
Autor principal:	Sohal, Sukhwinder Singh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720348/ https://www.ncbi.nlm.nih.gov/pubmed/29271974 http://dx.doi.org/10.2147/COPD.S154897

Ejemplares similares

Fluticasone furoate/fluticasone propionate – different drugs with different properties
por: Biggadike, Keith
Publicado: (2011)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
por: Papi, A, et al.
Publicado: (2017)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice
por: Patterson, Craig M, et al.
Publicado: (2012)

Beneficial Immunomodulatory Effects of Fluticasone Propionate in Chlamydia pneumoniae-Infected Mice
por: Paróczai, Dóra, et al.
Publicado: (2021)

Fluticasone Propionate Liposomes for Pulmonary Delivery
por: Nirale, N. M., et al.
Publicado: (2009)

No dose effect observed with chronic fluticasone propionate on growth velocity in children
por: Lee, Laurie A., et al.
Publicado: (2020)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD)
por: Sohal, Sukhwinder Singh, et al.
Publicado: (2013)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis
por: Wei, Zhengbo, et al.
Publicado: (2023)

Essential need for rethink of COPD airway pathology: implications for new drug approaches for prevention of lung cancer as well as small airway fibrosis
por: Sohal, Sukhwinder Singh, et al.
Publicado: (2017)

Degradation rates and products of fluticasone propionate in alkaline solutions
por: Tokumura, Tadakazu, et al.
Publicado: (2017)

Fluticasone-propionate: COVID-19 infection: case report
Publicado: (2020)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Effects of Fluticasone Propionate on Klebsiella pneumoniae and Gram-Negative Bacteria Associated with Chronic Airway Disease
por: Begley, Lesa A., et al.
Publicado: (2022)

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
por: Papi, Alberto, et al.
Publicado: (2015)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
por: Heijink, I. H., et al.
Publicado: (2016)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies
por: Siler, Thomas M., et al.
Publicado: (2016)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells
por: Berger, William E, et al.
Publicado: (2020)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis
por: Melnikova, Vladislava O., et al.
Publicado: (2008)

Therapeutic Modalities for Asthma, COPD, and Pathogenesis of COVID-19: Insights from the Special Issue
por: Sohal, Sukhwinder Singh
Publicado: (2022)

Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague
por: Crane, Samantha D., et al.
Publicado: (2022)

Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
por: Choi, Jae-Hwa, et al.
Publicado: (2021)

Endothelial to mesenchymal transition (EndMT): an active process in Chronic Obstructive Pulmonary Disease (COPD)?
por: Sohal, Sukhwinder Singh
Publicado: (2016)

Fluticasone Furoate, a Novel Inhaled Corticosteroid, Demonstrates Prolonged Lung Absorption Kinetics in Man Compared with Inhaled Fluticasone Propionate
por: Allen, Ann, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_irna999cngjmfegviniv1comal